Namwiwat Medical Corporation Public Company Limited

As of June 30, 2026, Namwiwat Medical Corporation Public Company Limited carries a market capitalization of 2.39B, placing it among publicly traded companies globally. Its enterprise value stands at 2.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Namwiwat Medical Corporation Public Company Limited's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Namwiwat Medical Corporation Public Company Limited has 700.00M shares outstanding.

As of June 30, 2026, Namwiwat Medical Corporation Public Company Limited trades at a trailing price-to-earnings ratio of 25.32. The price-to-sales ratio is 1.42, and the price-to-book ratio stands at 1.19.

As of June 30, 2026, Namwiwat Medical Corporation Public Company Limited trades at an EV/EBITDA multiple of 10.68 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.16 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Namwiwat Medical Corporation Public Company Limited trades at an EV/FCF ratio of 128.52, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.28B versus a market cap of 2.39B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Namwiwat Medical Corporation Public Company Limited maintains a current ratio of 3.37, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.37, indicating elevated leverage, while an interest coverage ratio of 11.76 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Namwiwat Medical Corporation Public Company Limited posted a return on equity (ROE) of 4.69, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.10 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.22, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.18, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.54 indicates how many times Namwiwat Medical Corporation Public Company Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Namwiwat Medical Corporation Public Company Limited recorded 25.86M in income tax expense. That works out to an effective tax rate of 21.23, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 121.81M, leaving 94.55M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Namwiwat Medical Corporation Public Company Limited's stock has declined approximately 18.00% over the past 52 weeks. The 50-day moving average sits at 3.24, while the 200-day moving average is 3.52.

Over the twelve months ended June 30, 2026, Namwiwat Medical Corporation Public Company Limited generated 1.69B in revenue and converted that into 94.55M in net income, yielding earnings per share of 0.14. EBITDA reached 212.97M, while operating income came in at 120.26M.

As of June 30, 2026, Namwiwat Medical Corporation Public Company Limited holds 687.80M in cash and equivalents against 472.00M in total debt, resulting in a net debt position of -291.27M. Total book value stands at 2.01B, with working capital of 1.44B providing operational flexibility.

Namwiwat Medical Corporation Public Company Limited produced 72.80M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -69.36M in capital expenditures, free cash flow totaled 3.44M - equivalent to 0.00 per share.

Over the twelve months ended June 30, 2026, Namwiwat Medical Corporation Public Company Limited posted a gross margin of 30.77, reflecting its pricing power and cost economics. The operating margin of 7.12 and net profit margin of 5.60 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Namwiwat Medical Corporation Public Company Limited paid dividends of 0.18 per share. The dividend payout ratio of 126.23 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 0.14, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.28, meaning Namwiwat Medical Corporation Public Company Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Namwiwat Medical Corporation Public Company Limited has an Altman Z-Score of 3.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.